Secondary Hyperparathyroidism Treatment | Parsabiv® (etelcalcetide)

Indication and Limitations of Use:

  • Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Read More
  • Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations. Close
Read Less
image of nephrologist
image of nephrologist

I’LL DO ALL I CAN
TO PRESCRIBE
WHAT I BELIEVE
IS
RIGHT FOR MY
PATIENT.

There’s more than one reason
why Parsabiv® is prescribed
by nephrologists for their clinically appropriate patients.

image of nephrologist
image of nephrologist

I WILL ADVOCATE
FOR THE
TREATMENT I
BELIEVE IS RIGHT
FOR MY PATIENT.

There’s more than one reason why Parsabiv® is used by dialysis care teams for their clinically appropriate patients.

image of nephrologist
image of nephrologist

WHEN A
TREATMENT’S
RIGHT FOR MY
PATIENT, I'LL
STAND BEHIND IT.

There’s more than one reason
why Parsabiv® is prescribed by nephrologists for their clinically appropriate patients.

image of dialysis nurse
image of dialysis nurse

I WILL WORK HARD
FOR A TREATMENT
WHEN I BELIEVE
IT’S RIGHT FOR MY
PATIENT.

There’s more than one reason
why Parsabiv® is used by dialysis care teams for their clinically appropriate patients.

image of nephrologist
image of nephrologist

WHEN A
TREATMENT IS
RIGHT FOR MY
PATIENT, IT'S
WHAT
I PRESCRIBE.

There’s more than one reason why Parsabiv® is prescribed by nephrologists for their clinically appropriate patients.

Parsabiv®® gives you control over calcimimetic delivery at the end of hemodialysis1

CONTROL

delivery with IV administration1
sHPT labs lowering graphic

LOWER

3 key secondary HPT lab values1,*
sHPT labs maintaining graphic

MAINTAIN

lab reductions up to 78 weeks1,†

*Results are combined from two 26-week, randomized, double-blind, placebo-controlled studies comparing Parsabiv® (etelcalcetide) with placebo in patients with chronic kidney disease (CKD) on hemodialysis.

† Open-label extension (OLE): data pooled for patients receiving Parsabiv® across two placebo-controlled parent studies and a subsequent OLE study, starting from the baseline of the parent study until the end or the prespecified cutoff date of the OLE study, whichever was earlier.2

Images of 3 Peer Advocates for Parsabiv: Dr. Henner, Dr. Abdellatif, and Ms. Dillon

Hear real nephrology professionals talk about their
experiences with Parsabiv®, including how Parsabiv® works

Learn from the experiences of
nephrologists and other peers
about how Parsabiv® (etelcalcetide)
performs in the real world

Learn More

Nephrologist Dr. Sprague
provides an overview of
sHPT
and an introduction
to Parsabiv®

Learn more about the first and only IV calcimimetic, including mechanism of action1

Parsabiv® is the first and only IV calcimimetic1

While Parsabiv® (etelcalcetide) and oral cinacalcet are both calcimimetics, these are two distinctly different drugs. See the mechanism of action for Parsabiv® and oral cinacalcet below

Parsabiv®

Directly targets the CaSR and lowers the threshold1,3-5 for receptor activation by Ca2+
  • Binds directly to the extracellular domain of the CaSR1,3
  • Synthetic peptide3
  • Steady state reached in 7-8 weeks1
Parsabiv®
Oral cinacalcet
Ca = calcium; CaSR = calcium-sensing receptor.

Oral cinacalcet

Directly targets the CaSR and lowers the threshold3,6,7 for receptor activation by Ca2+
  • Binds to the transmembrane domain of the CaSR3,6,7
  • Small molecule compound7
  • Steady state reached within 7 days6
Parsabiv®
Oral cinacalcet

Parsabiv®

Directly targets the CaSR and lowers the threshold1,3-5 for receptor activation by Ca2+
  • Binds directly to the extracellular domain of the CaSR1,3
  • Synthetic peptide3
  • Steady state reached in 7-8 weeks1
Ca = calcium; CaSR = calcium-sensing receptor.

Oral cinacalcet

Directly targets the CaSR and lowers the threshold3,6,7 for receptor activation by Ca2+
  • Binds to the transmembrane domain of the CaSR3,6,7
  • Small molecule compound7
  • Steady state reached within 7 days6
Icon_Efficacy

EFFICACY

See how Parsabiv® performed
in clinical trials and its use in real-world outcomes

Learn More
Real-World Evidence graphic

REAL-WORLD EVIDENCE

See an analysis from
hundreds of real-world treatment experiences

Learn More
Care TEam Corner Icon

CARE TEAM CORNER

Parsabiv® videos and information
specifically for dietitians, nurses, and technicians

Learn More
See More

Important Safety Information for Parsabiv®

Contraindication: Parsabiv® (etelcalcetide) is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. Hypersensitivity reactions, including face edema and anaphylactic reaction, have occurred.

Hypocalcemia: Parsabiv® lowers serum calcium and can lead to hypocalcemia, sometimes severe. Significant lowering of serum calcium can cause QT interval prolongation and ventricular arrhythmia. Patients with conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia due

Close

Important Safety Information for Parsabiv®

Contraindication: Parsabiv® (etelcalcetide) is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. Hypersensitivity reactions, including face edema and anaphylactic reaction, have occurred.

Hypocalcemia: Parsabiv® lowers serum calcium and can lead to hypocalcemia, sometimes severe. Significant lowering of serum calcium can cause QT interval prolongation and ventricular arrhythmia. Patients with conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia due to Parsabiv®. Closely monitor corrected serum calcium and QT interval in patients at risk on Parsabiv®.

Significant reductions in corrected serum calcium may lower the threshold for seizures. Patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to Parsabiv®. Monitor corrected serum calcium in patients with seizure disorders on Parsabiv®.

Concurrent administration of Parsabiv® with another oral calcimimetic could result in severe, life-threatening hypocalcemia. Patients switching from cinacalcet to Parsabiv® should discontinue cinacalcet for at least 7 days prior to initiating Parsabiv®. Closely monitor corrected serum calcium in patients receiving Parsabiv® and concomitant therapies known to lower serum calcium.

Measure corrected serum calcium prior to initiation of Parsabiv®. Do not initiate in patients if the corrected serum calcium is less than the lower limit of normal. Monitor corrected serum calcium within 1 week after initiation or dose adjustment and every 4 weeks during treatment with Parsabiv®. Measure PTH 4 weeks after initiation or dose adjustment of Parsabiv®. Once the maintenance dose has been established, measure PTH per clinical practice.

Worsening Heart Failure: In Parsabiv® clinical studies, cases of hypotension, congestive heart failure, and decreased myocardial performance have been reported. Closely monitor patients treated with Parsabiv® for worsening signs and symptoms of heart failure.

Upper Gastrointestinal Bleeding: In clinical studies, 2 patients treated with Parsabiv® in 1253 patient years of exposure had upper gastrointestinal (GI) bleeding at the time of death. The exact cause of GI bleeding in these patients is unknown and there were too few cases to determine whether these cases were related to Parsabiv®.

Patients with risk factors for upper GI bleeding, such as known gastritis, esophagitis, ulcers or severe vomiting, may be at increased risk for GI bleeding with Parsabiv®. Monitor patients for worsening of common Parsabiv® GI adverse reactions and for signs and symptoms of GI bleeding and ulcerations during Parsabiv® therapy.

Adynamic Bone: Adynamic bone may develop if PTH levels are chronically suppressed.

Adverse Reactions: In clinical trials of patients with secondary HPT comparing Parsabiv® to placebo, the most common adverse reactions were blood calcium decreased (64% vs. 10%), muscle spasms (12% vs. 7%), diarrhea (11% vs. 9%), nausea (11% vs. 6%), vomiting (9% vs. 5%), headache (8% vs. 6%), hypocalcemia (7% vs. 0.2%), and paresthesia (6% vs. 1%).

Indication

Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Limitations of Use: Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.

Limitations of Use: Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.

Please see Parsabiv® (etelcalcetide) full Prescribing Information.

References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.